ARTICLE | Product Development
Ace of BACE
May 5, 2008 7:00 AM UTC
Pharma companies have been working on beta secretase as a target for Alzheimer's disease for several years, but problems getting inhibitors across the blood-brain barrier have so far prevented them from getting into the clinic.
Astellas Pharma Inc. has in-licensed rights to the only compound that has overcome that obstacle and made it into human testing, CTS-21166, a beta secretase (BACE1) inhibitor from CoMentis Inc. that has completed a Phase I trial to treat AD...